Who Optimizes SG&A Costs Better? United Therapeutics Corporation or Alpine Immune Sciences, Inc.

Biotech Giants' SG&A Strategies: A Decade of Cost Management

__timestampAlpine Immune Sciences, Inc.United Therapeutics Corporation
Wednesday, January 1, 20142287709381287000
Thursday, January 1, 20156844000452612000
Friday, January 1, 20168586000316800000
Sunday, January 1, 20176079000330100000
Monday, January 1, 20188362000265800000
Tuesday, January 1, 20199467000336200000
Wednesday, January 1, 202010899000423900000
Friday, January 1, 202114560000467000000
Saturday, January 1, 202217968000487000000
Sunday, January 1, 202322222000477100000
Loading chart...

Cracking the code

Optimizing SG&A Costs: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. United Therapeutics Corporation and Alpine Immune Sciences, Inc. offer a fascinating comparison in this regard. Over the past decade, United Therapeutics has consistently maintained higher SG&A expenses, peaking at nearly $487 million in 2022. In contrast, Alpine Immune Sciences, with a more modest budget, saw its SG&A costs rise from approximately $2.3 million in 2014 to $22.2 million in 2023, marking a tenfold increase. This growth reflects Alpine's strategic investments in scaling operations. Meanwhile, United Therapeutics' expenses have fluctuated, indicating a dynamic approach to cost management. As both companies navigate the biotech landscape, their differing strategies in optimizing SG&A costs highlight the diverse paths to achieving operational efficiency and market success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025